1 / 83

Global Clinical Trial Patient Recruitment Services Market Analysis Sample Report

The Global clinical trial patient recruitment services market is projected to grow from $ 0.84 Mn in 2022 to $1.56 Bn by 2030, registering a CAGR of 8% during the forecast period of 2022-30. The Global clinical trial patient recruitment services market is a rapidly growing market that provides services to support the recruitment of patients for clinical trials. To get a detailed report, contact us at - info@insights10.com

Insights4
Download Presentation

Global Clinical Trial Patient Recruitment Services Market Analysis Sample Report

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A sample report on Global Clinical Trial Patient Recruitment Services Includes Market Size, Market Segmented by Types and Key Competitors (Data forecasts from 2022 – 2030F) www.insights10.com

  2. This report presents a strategic analysis of the Global Clinical Trial Patient Recruitment Services Market and a forecast for its development in the medium and long term. It provides a comprehensive overview of the market value, dynamics, segmentation, main players, growth and demand drivers, challenges & future outlook, etc. This is one of the most comprehensive reports about the Global Clinical Trial Patient Recruitment Services Market, and offers unmatched value, accuracy, and expert insights

  3. Report Scope Report Attribute Details Number of Pages 70-80 Base Year for Estimation 2022 Forecast Period 2023-2030 Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends, Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape, Reimbursement Scenario Report Coverage Quantitative Units Revenue in GlobalD Million/Billion (Mn/Bn) Research Approach Secondary Research (60%), Primary Research (40%) Click on the icon to know the detailed methodology 3 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  4. Table of Content CONTENT PG. NO. 12-25 1. Global Clinical Trial Patient Recruitment Services Market Overview 1.1. Overview 1.2. Global Overview 1.3. Economic Overview: Global 1.4. Clinical Trial Patient Recruitment Services Market in Global 1.5. Healthcare Scenario in Global 1.6. Health Insurance Coverage: Global 1.7. Budget of the Government for Public Insurance 1.8. Mergers and Acquisitions 26-30 2. Market Size and Forecasting 2.1 Market size and forecasts (Excel and Methodology) 4 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  5. Table of Content CONTENT PG. NO. 2.2. Market Segmentation 2.2.1. Market Segment 1 2.2.2. Market Segment 2 2.2.3. Market Segment 3 31-34 3. Market Dynamics 3.1. Market Growth Drivers 3.1.1. Global Clinical Trial Patient Recruitment Services Market Driver 1 3.1.2. Global Clinical Trial Patient Recruitment Services Market Driver 2 3.1.3. Global Clinical Trial Patient Recruitment Services Market Driver 3 3.2. Market Restraints 3.2.1. Global Clinical Trial Patient Recruitment Services Market Restraint 1 3.2.2. Global Clinical Trial Patient Recruitment Services Market Restraint 2 5 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  6. Table of Content CONTENT PG. NO. 3.2.3. Global Clinical Trial Patient Recruitment Services Market Restraint 3 35-45 4. Competitive Landscape 4.1. Major Market Share 4.2. Key Company Profile 4.2.1. IQVIA 4.2.1.1. Overview 4.2.1.2. Product Applications & Services 4.2.1.3. Recent Developments 4.2.1.4. Partnerships Ecosystem 4.2.1.5. Financials (Based on Availability) 4.2.2. AutoCruitment 4.2.2.1. Overview 6 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  7. Table of Content CONTENT PG. NO. 4.2.2.2. Product Applications & Services 4.2.2.3. Recent Developments 4.2.2.4. Partnerships Ecosystem 4.2.2.5. Financials (Based on Availability) 4.2.3. Antidote 4.2.3.1. Overview 4.2.3.2. Product Applications & Services 4.2.3.3. Recent Developments 4.2.3.4. Partnerships Ecosystem 4.2.3.5. Financials (Based on Availability) 4.2.4. BBK Worldwide 4.2.4.1. Overview 7 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  8. Table of Content CONTENT PG. NO. 4.2.4.2. Product Applications & Services 4.2.4.3. Recent Developments 4.2.4.4. Partnerships Ecosystem 4.2.4.5. Financials (Based on Availability) 4.2.5. CSSi 4.2.5.1. Overview 4.2.5.2. Product Applications & Services 4.2.5.3. Recent Developments 4.2.5.4. Partnerships Ecosystem 4.2.5.5. Financials (Based on Availability) 4.2.6. Elligo Health Research 4.2.6.1. Overview 8 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  9. Table of Content CONTENT PG. NO. 4.2.6.2. Product Applications & Services 4.2.6.3. Recent Developments 4.2.6.4. Partnerships Ecosystem 4.2.6.5. Financials (Based on Availability) 4.2.7. Praxis 4.2.7.1. Overview 4.2.7.2. Product Applications & Services 4.2.7.3. Recent Developments 4.2.7.4. Partnerships Ecosystem 4.2.7.5. Financials (Based on Availability) 4.2.8. Science37 4.2.8.1. Overview 9 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  10. Table of Content CONTENT PG. NO. 4.2.8.2. Product Applications & Services 4.2.8.3. Recent Developments 4.2.8.4. Partnerships Ecosystem 4.2.8.5. Financials (Based on Availability) 4.2.9. Trialspark 4.2.9.1. Overview 4.2.9.2. Product Applications & Services 4.2.9.3. Recent Developments 4.2.9.4. Partnerships Ecosystem 4.2.9.5. Financials (Based on Availability) 4.2.10. TrialX 4.2.10.1. Overview 10 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  11. Table of Content CONTENT PG. NO. 4.2.10.2. Product Applications & Services 4.2.10.3. Recent Developments 4.2.10.4. Partnerships Ecosystem 4.2.10.5. Financials (Based on Availability) 46-53 5. Reimbursement Scenario 5.1. Reimbursement Regulation 5.2. Reimbursement Process for Diagnosis 5.3. Reimbursement Process for Treatment 5.4 Reimbursement Process – Medicare 5.5 Reimbursement Process - Medicaid 54 6. Methodology & Scope 11 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  12. Global Clinical Trial Patient Recruitment Services Market Analysis 1. Global Clinical Trial Patient Recruitment Services Market Overview

  13. 1.1 Statistics at a Glance: The Scenario of Global Clinical Trial Patient Recruitment Services Market in the World Scope of Global Clinical Trial Patient Recruitment Services Market Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ $1.3 Mn Budgets for clinical trial funders have significantly increased, as have the costs associated with delays. If a clinical trial is delayed because of problems with recruitment, they could lose up to $1.3 Mn every day $779.5 Mn In 2022, the market for clinical trial patient recruiting services had been predicted to be worth $779.5 Mn In this section you will get an understanding of the topic, which includes the prevalence of the disease, the application of medical devices, new technology, and other details related to the topic ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 32% The most expensive part of clinical trials is patient recruitment, which accounts for 32% of overall costs 50.4% With the greatest revenue share of 50.4% in 2021, North America dominated the world market Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 13 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  14. 1.1 Statistics at a Glance: The Burden of Global Clinical Trial Patient Recruitment Services Market in the World (continued) Europe ~Revenue to reach $xx Bn by 2027 North America ~ Market Size of $xx Bn Asia -Fastest CAGR Africa ~Market Size of $xx Illustrative Illustrative 14 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  15. 1.2 Global Overview Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In this section you will get an understanding of the demographics of the country/region, which includes the population, GDP, healthcare expenditure and other details related to the topic ▪ 94.69Tn Is the Gross Domestic Product (GDP) in Global in 2021 7.97 Bn Is the Global population, in 2023 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 30 Is the median age in Global, in 2022 $10 Tn Public and private healthcare spending is anticipated to reach over $10 trillion globally by 2024. 15 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  16. 1.3 Economic Overview: Global Population of Global, (2020-2030) GDP of Global, (2020-2030) XX XX XX XX 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F Population Split (2023) In this section you will get an understanding of the demographics of the country/region, which includes the population, GDP, healthcare expenditure and other details related to the topic ▪ By Gender By Age Group In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 0-14 15-24 25-54 Male 49% Female 51% Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 55-64 65+ Illustrative Illustrative 16 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  17. 1.4 Global Healthcare Services Global Healthcare Services Market Forecast, 2022-2030 (in $Bn) xx xx xx xx xx xx xx xx xx 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In this section you will get an understanding of the overall Clinical Trial Patient Recruitment Services market in Global, which includes the market size, current trends and other details related to the topic ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Illustrative Illustrative 17 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  18. 1.5 Healthcare Scenario in World Clinical Trials Development Process: The process of developing a Clinical Trials is complex and involves many stages, from preclinical research to clinical trials to regulatory approval. Here is a simplified diagram of the Clinical Trials development process: Preclinical Research: Researchers identify potential drug candidates and test them in the lab Phase 1 Clinical Trials: Small studies are conducted to test the safety and dosage of the drug in humans Phase 2 Clinical Trials: Larger studies are conducted to test the effectiveness of the drug in treating Clinical Trials Phase 3 Clinical Trials: Even larger studies are conducted to compare the new drug to standard treatments and evaluate its safety and effectiveness Regulatory Approval: The drug is reviewed by regulatory agencies such as the FDA and approved for Globale in the Global market o o o o o FDA has developed several approaches to making drugs available as quickly as possible, while still ensuring their safety and effectiveness. Here are four of these approaches: Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serioGlobal conditions and fill an unmet medical need ▪ Fast Track A process designed to expedite the development and review of drugs which may demonstrate substantial improvement over available therapy Breakthrough Therapy ▪ These regulations allowed drugs for serioGlobal conditions that filled an unmet medical need to be approved based on a surrogate endpoint Accelerated Approval ▪ Priority Review A Priority Review designation means FDA’s goal is to take action on an application within 6 months ▪ Illustrative Illustrative 18 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  19. 1.6 Healthcare Scenario: Patient Journey Presentation Diagnosis Treatment Follow up Confirmatory Diagnosis Complete blood count (evaluate number & quality of RBCs, Hb & WBCs) Prevention and management of crisis: • For VOC and Splenic Sequestration: HU, Endari, Adakveo, Oxbryta • For infections: Antibiotics, Vaccines • Long term follow-up is required for patients with SCD • Annual assessment: CBC and reticulocyte count, iron statGlobal, liver and renal function tests, urinalysis, LDH, vitamin D level and neurocognitive assessment • ESOD (End Stage Organ Damage) evaluation starting from age 7 • Yearly Transcranial Doppler test to determine risk of stroke Initial Diagnosis Imaging (confirm bone related changes or respiratory problems) A sGlobalpected diagnosis is Globalually made, based on physical examination and detailed patient and family history Prenatal screening/ Neonatal screening Bacterial cultures of blood, sputum, urine, stool (detect any infection) Prevention and management of complications: • Stroke: Chronic transfGlobalions, HU Genetic testing (detect the type of SCD) Stakeholders PCP, pediatrician, neonatologist, endocrinologist, cardiologist, hematologist, orthopedist, psychologist and psychiatrist PCP, paediatrician, neonatologist, haematologist and genetic counsellor PCP, pediatrician, medical geneticist, cardiologist, hematologist, endocrinologist, psychologist and psychiatrist PCP, pediatrician, medical geneticist, hematologist, gynecologist and pathologist Depending on the organ complications, the treatment involves different specialists at different times Illustrative Illustrative 19 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  20. 1.7 Health Insurance Coverage: Global % of People by Type of Health Insurance Coverage (2021) Number of People By Health Insurance Coverage Coverage Type 2020 2021 Change % 8.3 Uninsured Total 327,521 328,074 91.7 With health insurance Any health plan 299,230 300,887 0.4 Any private plan 217,896 216,366 –0.6 66.0 Any private plan Employment-based 178,737 178,285 –0.2 54.3 Employment-based Direct-purchase 33,869 33,555 –0.1 10.2 Direct-purchase Marketplace coverage 10,924 11,389 0.1 3.5 Marketplace TRICARE 9,165 8,299 –0.3 2.5 TRICARE Any public plan 112,925 117,095 1.2 Medicare 58,541 60,226 0.5 35.7 Any public plan 18.4 Medicare Medicaid 58,778 61,940 0.9 18.9 Medicaid VA and CHAMPVA 2,967 3,151 0.1 1.0 VA and CHAMPVA Uninsured 28,291 27,187 –0.4 In 2021, most people (91.7%) had health insurance coverage at some point during 2021 and 8.3 % of people were uninsured for the entire calendar year More people had private health insurance (66%) than public coverage (35.7%) Employer-based insurance was the most common subtype of health insurance in the civilian, noninstitutionalized population (54.3%), followed by Medicaid (18.9%), Medicare (18.4%), direct-purchase insurance (10.2%), TRICARE (2.5%), and VA and CHAMPVA health care (1%) ▪ ▪ ▪ Illustrative Illustrative 20 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  21. 1.8 Budget of Global Government for Public Insurance Proposed Budget By Category 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2022-31 Outlays $769 $709 $766 $841 $840 $947 $1,014 $1,085 $1,227 $1,178 $1,325 $1,412 $10,633 Medicare In Billions Of Dollars $458 $521 $571 $582 $616 $645 $674 $698 $734 $768 $801 $837 $6,926 Medicaid 3.7% 3.2% 3.3% 3.4% 3.3% 3.6% 3.7% 3.8% 4.1% 3.8% 4.1% 4.2% 3.7% Medicare As % Of GDP 2.2% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.5% 2.5% 2.5% 2.5% 2.4% Medicaid National Health Expenditures (NHE) grew 2.7% to $4.3 trillion in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP) ▪ Medicare spending grew 8.4% to $900.8 billion in 2021, or 21% of total NHE ▪ Medicaid spending grew 9.2% to $734.0 billion in 2021, or 17% of total NHE ▪ Private health insurance spending grew 5.8% to $1,211.4 billion in 2021, or 28% of total NHE ▪ Out of pocket spending grew 10.4% to $433.2 billion in 2021, or 10% of total NHE ▪ Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 billion, or 14% oftotal NHE ▪ Hospital expenditures grew 4.4% to $1,323.9 billion in 2021, slower than the 6.2% growth in 2020 ▪ Physician and clinical services expenditures grew 5.6% to $864.6 billion in 2021, slower growth than the 6.6% in 2020 ▪ Prescription drug spending increased 7.8% to $378.0 billion in 2021, faster than the 3.7% growth in 2020 ▪ Largest shares of total health spending were sponsored by the federal government (34%) and the hoGlobaleholds (27%). The private bGlobaliness share of health spending accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7% ▪ Illustrative Illustrative 21 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  22. 1.9 Mergers and Acquisitions RCM M&A Deal Value Trend ($Bn) RCM M&A Deal Volume Trend $16.7 112 110 107 107 89 82 $11.7 $10.5 $7.7 $6.8 $6.0 1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022 1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022 Buyer Composition: Strategic Vs Financial (2020) Buyer Type by Deal Size ($Mn) 39% 41% 41% 42% 58% 59% 59% 61% Strategic Buyers Financial Buyers $0- $25 $25-$50 $50-$100 $100+ 57% of the total deal volume are done by strategic buyers and the rest 43% are done by financial buyers in 2020 Illustrative Illustrative 22 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  23. 1.9 Mergers and Acquisitions (continued) Latest Deals In Global Amount / Duration Company Name Type Year Key Pointers Oracle’s acquisition of Cerner is big tech’s latest foray into the healthcare system, promising better outcomes Oracle acquire Cerner through an all-cash tender offer for $95.00 per share, or approximately $28.3 Bn in equity value Cerner is a leading provider of digital information systems Globaled within hospitals and health systems to enable medical professionals to deliver better healthcare to individual patients and communities GSK has acquire BELLGlobal for Global$14.75 per share of common stock in cash representing an approximate total equity value of Global$2.0 billion ▪ ▪ Acquisition $28.3 Bn June, 2022 ▪ Oracle acquisition of Cerner ▪ BELLGlobal is a late-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough ▪ Acquisition $2 Bn April 2023 Acquisition further strengthens specialty medicines and respiratory pipeline with camlipixant, a highly selective P2X3 antagonist and potential best-in-class treatment for refractory chronic cough ▪ GSK acquisition of BELLGlobal Health Illustrative Illustrative 23 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  24. 1.9 Mergers and Acquisitions(continued) Latest Deals In Global Amount / Duration Company Name Type Year Key Pointers Merger March 2023 Merger Jan 2023 Illustrative Illustrative 24 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  25. Global Clinical Trial Patient Recruitment Services Market Analysis 2. Market Size and Forecasting

  26. 2.1 Market size and forecasts (Excel and Methodology) Click on the icon to know the methodology and assumption Global Clinical Trials Patient Recruitment Services Market Forecast, 2022-2030 (in $Bn) Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ XX XX In this section you will get an understanding of the overall Healthcare Insurance market in Malaysia, which includes the market size, current trends and other details related to the topic ▪ 2022 2023F 2024F 2025F 2026F 2025 2027F 2026 2028F 2027 2029F 2030F 2023 2024 2028 2029 2030 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Major Markets Patient (Mn) 2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12 Global Patient Size (Bn) 0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest Illustrative Illustrative ▪ % of Global Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45% Global Market Size (Bn $) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937 Global Market Size (Bn $) 61 74 84 87 91 95 99 106 26 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  27. 2.2 Snapshot of Global Clinical Trial Patient Recruitment Services Market Segmentation Therapeutics Areas Service Type Trial Phases Age Group Region Respiratory Diseases Child (Birth-17 Years) Patient Recruitment & Registry Services Phase I APAC Pain and Anaesthesia Adult (18 - 64 Years) Phase II North America Patient Retention Services Older Adults (65 Years+) Phase III Oncology Europe Central Nervous System Phase IV Africa Cardiovascular Middle East In this section you will get an understanding of the segmentations which will cover the Global Clinical Trial Patient Recruitment Services Market ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 27 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  28. 2.2.1 Market Segmentation: By Service Type Global Clinical Trials Patient Recruitment Services Market Share, By Service Type (2022) Patient Retention services market in Global is a significant component of the overall Clinical Trials treatment market ▪ It has the maximum market share in Global Clinical Trials market with approximately xx% ▪ Patient Recruitment & Registry Services Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Patient Retention Services In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 28 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  29. 2.2.2 Market Segmentation: By Trial Phases Global Clinical Trials Patient Recruitment Services Market Share, By Trial Phases (2022) Phase I market in Global is a significant component of the overall Clinical Trials market ▪ Phase IV It has the maximum market share in Global Clinical Trials market with approximately XX% ▪ Phase I Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Phase III In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Phase II 29 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  30. 2.2.3 Market Segmentation: By Therapeutics Areas Global Clinical Trials Patient Recruitment Services Market Share, Therapeutics Areas Respiratory Diseases Market have the maximum market share in Global Clinical Trials market with approximately xx% ▪ (2022) Cardiovascular Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Respiratory Diseases Central Nervous System In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Oncology Pain and Anaesthesia 30 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  31. 2.2.4 Market Segmentation: By Age Group Global Clinical Trials Patient Recruitment Services Market Share, By Age Group (2022) Child Birth market in Global is a significant component of the overall Clinical Trials market ▪ Older Adult It has the maximum market share in Global Clinical Trials market with approximately XX% ▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Child Birth In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Adult 31 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  32. 2.2.5 Market Segmentation: By Region Global Clinical Trials Patient Recruitment Services Market Share, By Region APAC Market have the maximum market share in Global Clinical Trials market with approximately xx% ▪ (2022) Middle East Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ APAC Africa In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Europe North America 32 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  33. Global Clinical Trial Patient Recruitment Services Market Analysis 3. Market Dynamics

  34. 3.1 Market growth drivers 3.1.1 More than 30% of clinical trials were registered in the US by February 2023, and it is projected that as a result of the considerable growth in clinical trials worldwide, which will ultimately lead to market expansion The growing need to develop new treatments for diseases and the rise in the number of clinical trials being conducted globally are driving the demand for patient recruitment services. ▪ Clinical Trials in Global This is driving the demand for Clinical Trials and creating opportunities for growth in the Clinical Trials market ▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 2010 2022 2030 34 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  35. 3.1 Market growth drivers (continued) 3.1.2 The cancer category had the biggest revenue share in 2021, with about 34.68%. The demand for drugs has accelerated due to the rise in cancer prevalence. Thus, this feature raises the need for clinical trials and, as a result, helps the market grow Top countries that are leveraging technology in their fight against Clinical Trials Global has a long history of investing in Clinical Trials research ▪ .The demand for medications and therapies to treat and manage the disease has increased as cancer is becoming more common. ▪ Norway Austria Denmark Belgium As a result of efforts by researchers and pharmaceutical corporations to create novel and efficient therapies, the need for clinical trials has increased. ▪ Spain Italy Netherlands Sweden Singapore In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Switzerland Israel Australia Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Canada France United Kingdom China South Korea Germany Japan Illustrative Illustrative United States 35 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  36. 3.2 Market restraints 3.2.1 Insufficient enrollment causes the termination of 34.68% of clinical trials before testing ever starts 3.2.2 84.68% of Clinical Trials fail to enroll adequate patients because of low patient awareness and participation 3.2.3 Demand for Clinical Trials care is expected to increase by 62.58% by 2035, while the supply is only expected to increase by 29.68% Inadequate enrolment can cause delays in the trial's execution or, in some situations, the trial's discontinuation if an insufficient number of participants is enlisted. Recruitment attempts may be hampered by patients' lack of knowledge about clinical trials and their potential advantages Many people can be unaware of the chance to take part in clinical trials or they might have preconceived notions about the procedure and hazards involved. Finding qualified and enthusiastic participants could become challenging as a result. There is a shortage of Clinical Trials in Global ▪ ▪ ▪ which can limit access to Clinical Trials ▪ ▪ and create barriers to growth in the Clinical Trials patient recruitment services market ▪ Enrollment challenges may be caused by elements like stringent qualifying requirements, low participant awareness, geographical restrictions, and other practical problems. ▪ ▪ Our analysis will thoroughly investigate the key restraints that may significantly impact bGlobaliness operations and growth. 36 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  37. Global Clinical Trial Patient Recruitment Services Market Analysis 4. Competitive Landscape

  38. 4.1 Major Market Share Revenue of Major players in Global Clinical Trials Patient Recruitment Services Market ($ Mn) Global Clinical Trials market is a highly competitive space, with many companies developing and marketing Clinical Trials treatments ▪ Other Some of the top companies in Global Clinical Trials market based on revenue and market share include ▪ IQVIA is a Swiss multinational healthcare company that develops and markets Clinical Trials treatments, including targeted therapies and immunotherapies ▪ In 2020, IQVIA's oncology sales were approximately $24 Bn, making it one of the largest players in Global Clinical Trials market ▪ XX Illustrative Illustrative 38 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  39. 4.2 Key Company Profile Key Note: 1 IQVIA Here is the list of top 10 companies which will cover in the final report ▪ 2 AutoCruitment Each company will have slides for ▪ 3 Overview Key details Offerings Name of products Recent activities/ Press Coverage Distribution and Vendor Partners Mergers, Acquisitions and Collaboration Financials If there are specific companies that you would like to be included in the report, please let Global know via email In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Antidote o o 4 BBK Worldwide o o 5 CSSi o 6 o Elligo Health Research o 7 Praxis o 8 Science37 ▪ 9 TrialSpark ▪ 10 TrialX 39 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  40. 4.2.1 IQVIA Solutions offered by IQVIA Founded in: 1982 ▪ The American multinational corporation IQVIA provides services to the combined fields of clinical trials and health information technology. ▪ IQVIA Direct-to-Patient recruiting helps remove barriers that increase time, cost, ▪ and uncertainty in recruiting efforts by utilizing machine learning and unprecedented patient data and insight. ➢ Safety Pharmacovigilance HQ: North Carolina, United States ➢ Medical Information Type: Public ➢ Commercial Compliance Revenue: $14,410 Mn ➢ Clinical Trials Website: www.iqvia.com ➢ Patient Support Recent Activity / Press Coverage IQVIA and (RED) Declare a Groundbreaking Partnership to Support the Strengthening of the Laboratory System Global Oncology R&D Activity Remains High and More Patients Have Been Treated for Cancer, says IQVIA Institute for Human Data Science According to the IQVIA Institute, the use of medicines in the United States grew in 2022 while patient out-of-pocket expenses remained low. 40 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  41. 4.2.1 IQVIA (continued) Partnerships Ecosystem Major Distribution Partners Major Vendor Partners One of the largest pharmaceutical distributors in the United States, McKesson has been a long-standing distribution partner for IQVIA IQVIA has been working with SAP, a leading software company, to develop digital solutions for its healthcare products A leading Swiss biotechnology company, Lonza provides IQVIA with contract manufacturing services for the production of its biologics and pharmaceuticals Cardinal Health is a Fortune 500 healthcare services company that provides pharmaceutical distribution services to IQVIA It is one of the largest drugstore chains in the United States and Europe, and its extensive network of retail locations and distribution centers make it an important distribution partner for IQVIA IQVIA has a strategic partnership with Microsoft to leverage its cloud computing and AI technologies in the development of new healthcare products Thermo Fisher Scientific is a leading provider of analytical instruments, reagents, and laboratory services A leading healthcare services provider in Asia, Zuellig Pharma is a distribution partner for IQVIA in several Asian countries GE Healthcare provides IQVIA with advanced medical imaging and diagnostics technologies, including CT scanners and MRI machines Illustrative Illustrative One of the largest pharmaceutical wholesalers in Europe, PHOENIX Group distributes IQVIA's products in several European countries 41 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  42. 4.2.1 IQVIA (continued) Latest Deals - Mergers and Acquisitions Amount / Duration Company Name Type Year Key Pointers IQVIA and Lilly will collaborate on the development of IQVIA Diagnostics’ Elecsys Amyloid Plasma Panel Elecsys Amyloid Plasma Panel has demonstrated clinical performance and is currently undergoing additional investigation to ensure clinical validation Once approved, could help healthcare professionals to streamline the journey to diagnosis for more patients ▪ ▪ Collaboration - March, 2023 Lilly ▪ IQVIA to acquire GenMark Diagnostics for Global$ 24.05 per share with the expectation to close in the 2nd quarter of 2021 ▪ GenMark provides molecular diagnostic tests that are designed to detect multiple pathogens from a single patient sample ▪ Merger $1.8 Bn March 2021 GenMark Diagnostics GenMark’s ePlex platform delivers rapid and actionable results so clinicians can determine the caGlobale of infection and the most effective treatment, potentially saving lives and alleviating the healthcare burden ▪ Illustrative Illustrative 42 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  43. 4.2.1 IQVIA (continued) Revenues ($Bn), 2020-2030 According to IQVIA's 2020 financial report, the company had sales of CHF 58.3 Bn (Swiss Francs) in 2020 ▪ This is equivalent to approximately $63.3 Bn, based on exchange rates at the end of 2020 70.9 ▪ 70.3 63.3 Company's Pharmaceuticals Division generated sales of CHF 49.9 Bn in 2020, while the Diagnostics Division generated sales of CHF 8.4 Bn ▪ 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F Breakdown of Net Revenue by Segment, 2022 Revenue generated by IQVIA in 2020 reflects the company's continued growth and success in the healthcare indGlobaltry ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Illustrative Illustrative 1 2 3 4 43 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  44. 4.2.2 Company 2 Solutions offered by Company Founded in: HQ: Type: Revenue: Website: Drugs for Clinical Trials Recent Activity / Press Coverage Drugs Indications Illustrative Illustrative 44 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  45. 4.2.2 Company 2 (continued) Partnerships Ecosystem Major Distribution Partners Major Vendor Partners Illustrative Illustrative 45 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  46. 4.2.2 Company 2 (continued) Latest Deals - Mergers and Acquisitions Amount / Duration Company Name Type Year Key Pointers Illustrative Illustrative 46 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  47. 4.2.2 Company 2 (continued) Revenues ($Bn), 2020-2030 Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ xx xx xx In this section you will the understating of financial overview of the company, which includes revenue forecasting, segment revenue and other key details as per availability ▪ 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Breakdown of Net Revenue by Segment, 2022 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Illustrative Illustrative 1 2 3 4 47 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  48. Global Clinical Trial Patient Recruitment Services Market Analysis 5. Reimbursement Scenario

  49. 5.1 Reimbursement Regulation Medicare and Medicaid together provide health insurance coverage for more than 4 in 10 Americans The reimbursement scenario in the Global Clinical Trials market is complex and can vary depending on the specific treatment, setting of care, and insurance coverage. Here are some key points to consider: Medicare: o ▪ Medicare is a federal health insurance program for people aged 65 and older, as well as people with certain disabilities or health conditions Medicare covers many Clinical Trials treatments, including chemotherapy, radiation therapy, and some immunotherapies However, coverage can be subject to strict guidelines and restrictions, such as the requirement for prior authorization Medicaid: o Medicaid is a joint federal-state program that provides health insurance for people with low incomes o Medicaid coverage for Clinical Trials treatments can vary by state, and may be subject to limits on the amount and type of treatment covered Private Insurance: o Private insurance coverage for Clinical Trials treatments can also vary widely depending on the insurer and the specific policy o Some policies may have high out-of-pocket costs, such as deductibles and co-pays, while others may have more comprehensive coverage Other Public 1% o Other Private 3% Uninsured 9% Medicare 17% o ▪ Medicaid and CHIP 21% ▪ Employer-Sponsored 49% Health Insurance Coverage, 2022 Illustrative Illustrative 49 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

  50. 5.1 Reimbursement Regulation (continued) Affordable Care Act: Affordable Care Act (ACA) includes provisions to help improve access to Clinical Trials treatments by requiring insurers to cover certain preventive services, including Clinical Trials screenings, without co-pays or deductibles It also includes protections for people with pre-existing conditions, such as Clinical Trials Reimbursement for New Treatments: Reimbursement for new Clinical Trials treatments can be a complex and lengthy process, as insurers and government programs often require evidence of safety and effectiveness before providing coverage This can create challenges for companies developing and marketing new treatments Value-Based Care: There is a growing trend towards value-based care, which aims to improve outcomes and lower costs by focGlobaling on the value of treatments rather than simply the volume of treatments Value-based care models can include payment models that tie reimbursement to outcomes or performance metrics ▪ o o ▪ o o ▪ o o In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest Illustrative Illustrative 50 A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential

More Related